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ABSTRACT
Background
To explore the possibility that antibody-mediated complement lysis contributes to viremia
control in HIV-1 infection, we measured the activity of patient plasma in mediating
complement lysis of autologous primary virus.
Methods and Findings
Sera from two groups of patients—25 with acute HIV-1 infection and 31 with chronic
infection—were used in this study. We developed a novel real-time PCR-based assay strategy
that allows reliable and sensitive quantification of virus lysis by complement. Plasma derived at
the time of virus isolation induced complement lysis of the autologous virus isolate in the
majority of patients. Overall lysis activity against the autologous virus and the heterologous
primary virus strain JR-FL was higher at chronic disease stages than during the acute phase.
Most strikingly, we found that plasma virus load levels during the acute but not the chronic
infection phase correlated inversely with the autologous complement lysis activity. Antibody
reactivity to the envelope (Env) proteins gp120 and gp41 were positively correlated with the
lysis activity against JR-FL, indicating that anti-Env responses mediated complement lysis.
Neutralization and complement lysis activity against autologous viruses were not associated,
suggesting that complement lysis is predominantly caused by non-neutralizing antibodies.
Conclusions
Collectively our data provide evidence that antibody-mediated complement virion lysis
develops rapidly and is effective early in the course of infection; thus it should be considered a
parameter that, in concert with other immune functions, steers viremia control in vivo.
The Editors’ Summary of this article follows the references.
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The humoral immune response to HIV-1 infection is
elicited early in infection and is generally vigorous at later
disease stages, but its efﬁcacy and modes in controlling
viremia in vivo have not yet been completely unraveled.
While numerous studies suggest that neutralizing antibodies
may impact viral replication in vivo [1–7], the effect of
antibodies in mediating effector functions and in limiting
viral spread via the complement system, phagocytic cells, or
killer cells remains uncertain. A detailed characterization and
quantiﬁcation of the relative contribution of direct and
effector-mediated antibody functions on virus containment
in vivo will be of central importance in deﬁning relevant
immune responses and designing vaccines.
The complement system is a key component of innate
immune defense, and it provides a link to the adaptive
immune response [8–10]. Besides inducing direct lysis of
pathogens, the complement system also has opsonizing,
phagocytosis-inducing, chemoattractant, and immune stim-
ulatory functions [8,11]. Speciﬁc antibody alone can efﬁ-
ciently neutralize many viruses, but complement activation
can enhance the antiviral effects of antibodies by opsonizing
virions or inducing lysis of the particles [11]. Complement is
effective in lysing many enveloped viruses, resulting in
fragmentation of the outer membrane and disintegration of
the nucleocapsid [11].
The role of complement in HIV pathogenesis appears to be
multifaceted [12,13]. HIV-1 virions can activate complement
via the classical pathway either by antibodies bound to the
virus surface or, independent of antibody, by direct activa-
tion of complement through the viral envelope (Env) proteins
gp41 and gp120 [14–17]. Direct lysis of HIV-1 upon antibody-
mediated activation of the complement system has been
demonstrated in vitro [18–20]. Complement has further been
shown to boost the activity of neutralizing antibodies in vivo
and in vitro [21,22], and non-neutralizing antibodies may play
a role in containing viremia during the acute phase of
infection by inducing direct complement-mediated virus lysis
[23].
Opposing these observations, several reports have sug-
gested that complement lysis of HIV-1 is limited in vivo by
several host cell-derived complement control proteins in-
corporated by the HIV-1 virions [24–26]. Since antibody and
complement efﬁciently lead to opsonization but not always to
destruction of HIV-1, the virus may remain infectious [27]. In
addition, opsonized virions were found to bind to comple-
ment receptor-expressing cells, which can enhance viral
infectivity and transmission in vitro [12,13,28–31].
In the present study we sought to investigate the question
of whether antibody-mediated complement lysis of HIV-1
contributes to virus containment in vivo and, if so, to
quantify the relative contribution of this defense mechanism
at different disease stages.
Methods
Patients and Virus Isolates
The study included 25 acutely infected and 31 chronically
infected patients (Table 1). A control group of 11 healthy
HIV-1 negative donors was recruited from volunteers
afﬁliated with the University Hospital Zurich (Table S1).
Patient demographics and selection and isolation of autolo-
gous virus have been described [32,33]. Written informed
consent was approved by the ethics committee of the
University Hospital Zurich and was obtained from all
individuals (both infected and uninfected) according to the
guidelines of the University Hospital Zurich.
Plasma
Patient blood was sampled in Vacutainer tubes containing
EDTA (BD [http://www.bd.com]), and plasma was collected
within 6 h and frozen in 1 ml aliquots at  75 8C. Plasma was
heat inactivated (1 h at 56 8C) to destroy complement activity
and centrifuged at 500g for 10 min before use to remove cell
debris and lipids. Normal plasma and infected-patient plasma
were treated identically.
HIV-1 Virion Complement Lysis Assay
A mix of sera from one to ﬁve healthy donors, stored at 75
8C, was used as source of complement.
HIV-1 virus stock (25 ll) was incubated with 20 ll of patient
plasma (ﬁnal dilution 1:5), 50 ll of complement (NHS ﬁnal
dilution 1:2), and 1 ll of RNase A (Qiagen, Valencia,
California, United States) in RPMI 1640 (BioWhittaker
[http://www.cambrex.com]) for a total volume of 100 ll; this
mixture was incubated for 3 h at 37 8C (Figure 1). The
reaction mixture was frozen at  208 C, thawed, and treated
with RNase A (0.77 mg/ml, Qiagen) and DNase I (0.92 mg/ml)
(Roche [www.roche-applied-science.com]) for 1 h at 378 Ci na
thermoshaker (Eppendorf; 1,400 rpm). Samples were treated
with protease (0.71 mg/ml) (Qiagen) to remove RNase and
DNase activity. Residual viral RNA in intact virions was
extracted (RNeasy Mini Kit, Qiagen) and quantiﬁed by real-
time PCR.
The extraction efﬁciency was controlled by adding and
quantifying synthetic murine prion protein (PrP) mRNA
(7,866 copies/ll) as an internal standard. In each assay,
samples were tested in triplicate. Complement-mediated lysis
activity was expressed as the percentage of lysed HIV-1 RNA
copies compared to control plasma treatment. A mixture of
plasma from 1–5 HIV-1-negative donors was used as negative
control (no lysis activity, 0% value).
Real-Time PCR
HIV-1 virions were quantiﬁed using primers either to Gag
or to the 59 end of HIV-RNA. For detection, dual-labeled
ﬂuorescent probes with a ﬂuorescein (FAM) moiety at the 59
ends and a tetramethylrhodamine (TAMRA) moiety at the 39
end were used. HIV-Gag was measured using primers skcc1b
[34] for cDNA synthesis, primers ts59gag (upstream; 59-
CAAGCAGCCATGCAAATGTTAAAAGA-39), boe2 (down-
stream), and boe3 (probe) [35] for ampliﬁcation and
detection. HIV-59 RNA was measured using primer mf86
(59-CCACACTGACTAAAAGGGTCTGAGGGATCT-39), cr1
(59-TCTCTGGCTAACAGGGAACCCACTGCTT-39), cr2 (59-
TGACTAAAAGGGTCTGAGGGATCTCTAGTTACCAG-39),
and mf74tq (FAM-59-AGCACTCAAGGCAAGCTTTATT-
GAGGC-39-TAMRA). PrP mRNA was measured using PCR
primers as previously described [36] and using a ﬂuorescent
probe prpe2þtq (FAM-59-CAACCGAGCTGAAG-
CATTCTGCCT-39-TAMRA). PCR was performed as described
previously [37,38] in a single-tube system (Qiagen 1-step RT-
PCR) with an additional ‘‘hot-start’’ using Ampliwax (Applied
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cDNA synthesis and PCR ampliﬁcation steps. cDNA synthesis
and subsequent ampliﬁcation were performed in duplicate in
a real-time thermocycler (i-Cycler [BioRad, Hercules, Cal-
ifornia, United States]) as described [37,38].
Anti-gp120, Anti-gp41, and Anti-p24 Plasma Antibody
Titer
Plasma IgG titers to recombinant gp120 from the JR-FL
strain (kindly provided by W. Olson, Progenics, Tarrytown,
New York, United States), recombinant gp41 (amino acids
541–682 of the HxB2 strain [Viral Therapeutics, Ithaca, New
York, United States]) and recombinant p24 (IIIB [Aalto
BioReagents, Dublin, Ireland]) were determined by ELISA as
described [32].
Plasma IgG titers to recombinant gp41 were determined as
described for the other two antigens using plates coated with
0.1 lg of gp41 per well (amino acids 541 to 682 of the HxB2
strain; Viral Therapeutics). Maximal binding to gp41 was
deﬁned using the antibody 2F5 (kindly provided by H.
Katinger) as a reference. Detection of bound antibody and
calculation of midpoint titers were done as described [32].
IgG Antibody Depletion
IgG was depleted from patient plasma using Protein G
Sepharose beads (Amersham Pharmacia [http://www.
amershambiosciences.com]). Beads were washed with PBS
and incubated with patient plasma at room temperature for 1
h. Beads were removed by centrifugation and IgG-depleted
plasma was taken from the supernatant.
Neutralization Assays
Neutralization activity of patient plasma against replica-
tion competent autologous primary virus isolates was
evaluated on peripheral blood mononuclear cells as de-
scribed [39]. The plasma dilution over 1:40 causing 90%
reduction (neutralization titer, NT90) in p24 production was
determined by regression analysis.
Neutralization activity of patient plasma against the
heterologous virus isolate JR-FL was evaluated on TZM-bl
cells (National Institutes of Health AIDS Research and
Reference Reagent Program) using JR-FL Env pseudotyped
virus as described [4,40]. The plasma dilution over 1:20
causing 50% reduction (NT50) in luciferase reporter gene
production was determined by regression analysis.
Effects of Active Complement on Antibody-Mediated
Inhibition of Viral Infectivity
Inhibitory activity of patient plasma in the presence of
active or heat-inactivated complement was evaluated using
JR-FL Env pseudotyped virus on TZM-bl cells [4,40]. Patient
plasma (1:5 or 1:25 for acute and chronic patients, respec-
tively) and complement in the same ratios as for the HIV-1
virion complement lysis assay were preincubated with virus
(TCID50 ¼ 1,000 ml
 1) for 3 h at 37 8C without a subsequent
freeze-thaw cycle (total volume, 60 ll). Plasma and comple-
ment content of the virus control were adjusted to the
corresponding sample dilution with uninfected control
plasma and active or inactivated complement, respectively.
After preincubation, inhibition was measured in duplicates
on TZM-bl cells at a ﬁnal plasma concentration of 1:40 or
1:200 for acute and chronic patients, respectively.
Statistical Analysis
Data analyses were performed using Prism version 4.03 for
Windows (GraphPad Software, San Diego, California, United
States) and Stata SE/9.2 for Windows (Stata Corporation,
College Station, Texas, United States). The normality
assumption was checked using the D’Agostino and Pearson
omnibus normality test and had to be rejected for most
variables (unpublished data). Hence, nonparametric methods
were employed for testing of group differences (Mann-
Whitney U test and Wilcoxon signed-rank test for unpaired
and paired testing, respectively). Correlation analysis was
performed using Spearman’s rank correlation. All tests of
signiﬁcance were two-tailed and the level of signiﬁcance was
set at 0.05. P values reported in the main text and ﬁgures
refer to values obtained after singular testing. Since multiple
testing was performed caution must be taken in evaluating
signiﬁcance. In sum, 47 tests of signiﬁcance were performed
in our study, thus our level of signiﬁcance was set at p ,
0.00106 after Bonferroni correction to adjust for multiple
testing. This stringent approach does not alter any of our
main conclusions
Results
Antibodies in Patient Plasma Mediate Complement Lysis
Activity against Autologous Viruses
The primary intent of this study was to evaluate the
inﬂuence of antibody- and complement-mediated lysis on
viremia control in vivo. To this end we utilized an assay
strategy that allows reliable and sensitive quantiﬁcation of
virus lysis by complement. In order to probe complement
lysis activity under in vivo-relevant conditions, virus prepa-
rations used in our study were derived from infected primary
peripheral blood mononuclear cells, because these cells are
known to incorporate high numbers of complement control
proteins, rendering these viruses less susceptible to comple-
ment lysis than those produced on immortalized cell lines
[24]. In our assay, incubation of HIV-1 isolates with
autologous patient plasma and complement is followed by
one freeze-thaw cycle to completely disrupt the complement-
attacked virions (Figure 1). Released RNA from lysed virions
is digested by RNase treatment, and the RNase is inactivated
by protease digestion. Viral RNA from the remaining intact
virions is then extracted and quantiﬁed by real-time PCR.
Using this assay scheme we were able to detect substantial
complement lysis activity directed against the autologous
virus in patient sera (Figure 2A). Patient plasma sampled at
the time of virus isolation from a chronically infected
individual (patient 106) induced lysis of 71% of the
heterologous virus JR-FL in the presence of active comple-
ment. In the absence of active complement or of patient
plasma, no efﬁcient lysis was observed (lysis , 15%) (Figure
2A). Likewise, plasma from uninfected donors did not show
speciﬁc lysis activity in the presence of active complement.
We further validated our assay and ensured that freeze
thaw-cycles by themselves do not disrupt virions. As
previously described, we found that neither the single
freeze-thaw cycle used in our assay nor repeated cycles (2–
4) led to disintegration of the virus in the absence of patient
sera (Figure 2B) [41,42]. Irrespective of the isolate or plasma
tested, a minimum of 10% of the virions appeared to be
resistant to lysis. This resistant fraction may consist of viral
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e441 2080
Complement Lysis of HIV In VivoT
a
b
l
e
1
.
P
a
t
i
e
n
t
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
,
C
o
m
p
l
e
m
e
n
t
L
y
s
i
s
A
c
t
i
v
i
t
y
,
A
n
t
i
b
o
d
y
T
i
t
e
r
s
,
a
n
d
N
e
u
t
r
a
l
i
z
a
t
i
o
n
T
i
t
e
r
s
C
a
t
e
g
o
r
y
P
a
t
i
e
n
t
I
d
e
n
t
i
f
i
c
a
t
i
o
n
N
u
m
b
e
r
H
I
V
-
1
R
N
A
a
(
C
o
p
i
e
s
/
m
l
)
C
D
4
(
C
e
l
l
s
/
l
l
)
A
u
t
o
l
o
g
o
u
s
L
y
s
i
s
A
c
t
i
v
i
t
y
(
%
)
H
e
t
e
r
o
l
o
g
o
u
s
L
y
s
i
s
A
c
t
i
v
i
t
y
b
(
%
)
A
n
t
i
-
g
p
1
2
0
A
n
t
i
b
o
d
y
(
T
i
t
e
r
)
A
n
t
i
-
g
p
4
1
A
n
t
i
b
o
d
y
(
T
i
t
e
r
)
A
n
t
i
-
p
2
4
A
n
t
i
b
o
d
y
(
T
i
t
e
r
)
A
u
t
o
l
o
g
o
u
s
N
e
u
t
r
a
l
i
z
a
t
i
o
n
c
(
N
T
9
0
)
H
e
t
e
r
o
l
o
g
o
u
s
N
e
u
t
r
a
l
i
z
a
t
i
o
n
d
(
N
T
5
0
)
A
c
u
t
e
A
K
1
0
3
2
1
,
1
0
0
4
1
8
2
6
1
7
2
2
4
6
5
7
0
3
 
4
0
 
2
0
A
K
1
0
4
5
4
,
2
0
0
2
6
4
5
4
1
5
8
1
1
0
6
3
,
4
9
9
7
7
 
2
0
A
K
1
0
5
3
4
0
,
5
0
0
4
7
0
2
0
1
5
2
9
3
9
8
8
 
4
0
 
2
0
A
K
1
1
2
2
9
,
7
0
0
3
8
9
1
8
1
0
2
1
9
2
,
2
8
6
 
4
0
 
2
0
A
K
1
1
4
4
,
6
1
0
4
7
4
6
8
 
9
2
7
1
1
2
4
0
 
4
0
 
2
0
A
K
1
1
5
6
,
0
4
0
4
6
7
2
6
3
4
1
8
1
4
 
4
0
 
2
0
A
K
1
1
6
1
0
5
,
0
0
0
3
2
7
1
8
2
6
7
1
2
2
4
 
4
0
 
2
0
A
K
1
1
9
1
9
1
,
5
0
0
4
3
1
2
8
1
6
1
4
4
9
3
7
4
 
4
0
 
2
0
A
K
1
2
2
2
,
6
1
0
,
0
0
0
3
1
5
1
8
2
8
1
0
9
7
2
1
,
2
2
7
1
6
0
 
2
0
A
K
1
2
5
1
2
4
,
0
0
0
4
8
3
3
1
8
2
0
3
7
5
8
2
8
7
 
2
0
0
0
2
2
6
1
,
4
1
5
8
3
2
2
4
1
3
4
1
1
,
0
1
5
4
1
 
2
0
0
0
3
1
1
,
0
5
3
3
4
9
4
8
1
2
2
8
1
7
3
1
1
 
4
0
 
2
0
0
0
7
4
7
,
6
8
1
5
3
1
3
8
3
2
1
9
3
2
3
6
1
,
1
0
7
 
4
0
 
2
0
0
0
9
1
,
4
9
0
,
0
0
0
2
5
0
6
2
8
8
2
5
3
4
 
4
0
 
2
0
0
1
5
3
7
,
7
0
0
4
4
5
4
2
9
1
0
5
3
2
3
2
,
7
1
3
 
4
0
 
2
0
0
1
6
7
1
,
7
0
0
8
5
5
6
2
1
2
1
4
1
4
9
8
 
4
0
 
2
0
0
1
7
1
,
2
7
5
,
0
0
0
3
5
9
 
7
7
1
4
8
1
 
4
0
 
2
0
0
1
8
3
,
9
2
5
,
0
0
0
1
5
9
1
2
2
1
3
1
6
2
2
2
1
,
1
0
2
 
2
0
0
1
9
1
,
4
7
0
,
0
0
0
2
7
5
1
5
 
9
1
1
1
 
4
0
 
2
0
0
2
0
1
1
3
,
5
0
0
3
4
5
 
1
5
 
2
0
1
1
1
 
4
0
 
2
0
0
2
1
3
9
0
0
0
0
0
3
0
2
 
1
1
4
4
6
7
1
4
0
5
1
2
0
5
 
2
0
0
2
2
1
7
,
8
7
7
,
0
0
0
1
6
9
 
5
2
3
1
2
9
6
1
6
 
4
0
 
2
0
0
2
3
1
1
,
0
0
0
4
9
2
3
1
1
5
3
4
1
1
0
2
9
3
 
4
0
 
2
0
0
2
5
3
6
,
6
0
0
3
2
9
3
5
2
8
5
1
7
5
3
6
3
3
1
 
4
0
 
2
0
0
2
6
1
7
2
,
5
0
0
4
0
2
2
5
8
1
5
4
5
6
6
4
 
4
0
 
2
0
C
h
r
o
n
i
c
1
0
2
4
,
6
0
7
e
5
9
4
2
3
4
7
6
3
3
3
6
5
2
3
 
4
0
1
,
1
2
2
1
0
5
1
7
0
,
2
6
5
e
1
,
2
2
8
3
8
3
7
1
6
8
3
9
1
9
4
 
4
0
 
2
0
1
0
6
3
,
1
3
6
5
2
8
5
1
6
8
2
8
,
2
2
5
4
,
4
3
7
5
,
2
9
7
5
9
 
2
0
1
0
7
1
,
4
6
8
4
3
1
6
1
5
1
5
,
0
6
9
1
,
1
6
9
4
,
5
1
7
1
1
9
1
3
6
1
0
9
9
4
6
e
9
4
6
3
0
5
3
1
4
,
1
4
8
1
,
8
6
5
6
6
6
 
4
0
1
1
1
1
1
1
,
6
e
3
8
5
2
6
2
7
3
,
5
1
4
7
5
5
2
,
4
0
5
4
3
3
4
1
1
3
9
9
,
9
9
9
9
7
7
5
2
6
3
1
5
,
0
1
4
2
,
4
9
2
3
3
 
4
0
 
2
0
1
1
4
1
7
,
6
0
3
8
1
1
2
8
3
7
2
,
1
5
2
2
,
3
7
3
2
,
5
1
6
 
4
0
2
8
1
1
5
5
9
,
0
8
1
4
6
3
3
4
4
6
8
,
8
3
8
3
,
9
5
3
5
,
4
9
7
4
3
2
8
1
1
6
4
3
,
5
9
4
e
2
2
7
6
9
4
9
2
,
5
6
2
1
,
2
7
6
3
,
3
4
3
4
3
 
2
0
1
1
7
1
3
,
7
0
5
4
7
4
7
4
5
1
2
,
3
7
2
2
,
5
1
4
4
1
9
 
4
0
 
2
0
1
1
8
1
0
,
0
8
0
8
0
6
0
4
5
6
,
7
0
0
1
,
1
0
2
2
,
5
5
8
2
0
8
 
2
0
1
1
9
1
1
2
,
5
5
0
e
3
2
9
3
5
5
5
9
,
8
8
2
,
1
7
4
3
9
0
 
4
0
2
4
1
2
0
2
9
1
,
7
7
1
4
8
8
7
4
5
6
8
,
9
7
8
1
,
9
9
3
1
,
3
7
6
4
5
5
5
1
2
1
2
8
3
,
1
4
0
3
9
7
2
9
4
4
1
2
,
8
2
2
6
,
2
1
1
2
7
9
 
4
0
8
7
6
1
2
2
2
2
,
5
1
0
e
5
0
6
4
8
7
8
1
8
9
5
5
6
5
7
3
4
0
8
3
6
8
5
5
8
1
2
3
1
,
6
1
3
7
4
1
5
8
3
8
1
,
4
6
0
3
,
4
4
8
5
,
6
6
4
9
8
 
2
0
1
2
5
1
7
,
5
5
1
e
7
8
3
7
7
4
5
5
2
9
5
1
6
2
6
3
2
3
1
3
 
2
0
1
2
6
1
0
,
0
0
0
3
5
4
8
8
5
2
6
9
2
4
1
7
4
6
4
8
8
6
 
4
0
1
,
4
4
2
1
2
7
2
,
6
9
2
e
6
9
9
3
2
3
5
1
8
6
2
9
2
7
3
2
7
 
4
0
 
2
0
1
2
8
2
5
,
7
1
4
5
2
4
3
7
7
0
9
,
8
1
7
3
,
4
6
3
4
,
9
3
8
 
4
0
1
,
1
1
5
1
3
0
1
,
3
0
4
e
6
8
9
1
6
2
1
1
2
9
4
2
9
6
2
 
4
0
 
2
0
S
2
2
0
1
3
2
,
7
7
3
6
8
2
7
7
2
9
3
5
6
9
6
7
1
7
1
1
3
 
2
0
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e441 2081
Complement Lysis of HIV In Vivoparticles carrying mutated, no, or low numbers of Env
proteins, which could cause insufﬁcient recognition by
antibodies, or it may represent virus populations carrying
high numbers of complement control proteins as suggested
previously [24,43]. Neither increasing the plasma concen-
tration nor blocking the complement control protein CD59
rendered this fraction of virions fully susceptible to lysis
(unpublished data).
To determine if the observed virolysis activity depends on
antibodies, we depleted plasma from two patients of IgG
using Protein G Sepharose beads prior to incubation with
virus and complement (Figure 2C). Undepleted plasma of
patients 117 and 113 showed complement lysis activity of 40
and 36%, respectively. Depletion of IgG led to a substantial
decrease of the observed lysis to 15% and 19% lysis for
patients 117 and 113, respectively. The lysis activity observed
after protein G treatment likely resulted from IgM antibodies
and/or residual IgG. In summary, our data suggest that
substantial complement-mediated lysis activity against HIV-1
virions may be present in a patient’s autologous sera and that
a considerable proportion of this lysis activity depends on
IgG antibodies in a patient’s plasma.
Complement Lysis Activity in Plasma of Acutely and
Chronically HIV-1-Infected Individuals against Autologous
Virus
To explore the impact of antibody-mediated complement
virus lysis at different disease stages we measured patient
plasma complement virolysis activity against autologous virus
in a previously described cohort of 25 acutely and 31
chronically infected patients (Figure 3A and Table 1)
[32,33]. Lysis activity against the autologous virus was
measured in plasma samples derived at the time of virus
isolation. The fact that the extent of lysis measured in our
assay is independent of the amount of virus input (Figure S1)
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Figure 1. Schematic Overview of the Virion Lysis Assay
(A) Primary HIV-1 virions were incubated with autologous plasma and
complement and freeze-thawed once, and viral RNA was digested by
RNase and DNase. After inactivation of RNase and DNase by protease
and addition of an internal standard (PrP RNA), RNA was extracted and
quantified by real-time PCR.
(B) HIV-1 virions sensitive to antibody-mediated complement lysis were
disrupted, making viral RNA accessible for degradation.
(C) Viral RNA of complement lysis-resistant virions remained intact. RNA
was extracted and could be quantified by real-time PCR.
doi:10.1371/journal.pmed.0030441.g001
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Complement Lysis of HIV In Vivoallowed us to compare the activities of multiple divergent
virus isolates without normalizing virus input. The latter
process can be prone to error, because absolute quantiﬁca-
tion of highly divergent virus stocks is subject to sequence
variation and the resulting differences in RNA or p24
detection.
Virus input ranged from 4.8 310
3 to 6.3 3 10
7 viral RNA
copies. In two patients with very high viral load (patients 018
and 022), virus detected in the plasma contributed over 1% to
the total amount of HIV-1 copies measured in our assay.
Therefore, patient plasma and heat-inactivated complement
were used as negative control in these cases.
Autologous plasma induced complement lysis of the
respective virus in the majority of infected patients (Figure
3A). Nineteen of 25 acutely infected and 30 of 31 chronically
infected individuals showed speciﬁc lysis activity (over the
95% conﬁdence interval of normal controls, i.e., more than
5.8% lysis). Complement lysis activity was highly variable
between patients and ranged from 90% lysis to no lysis at a
plasma dilution of 1:5. The median of complement lysis was
almost twice as high during chronic disease stages (37.63%
lysis) than during the acute phase (19.89% lysis, p ¼ 0.001,
Mann-Whitney U test) (Figure 3A and Table 2).
Complement Lysis Activity in Plasma of Acutely and
Chronically HIV-1-Infected Individuals against the
Heterologous Strain JR-FL
Antibody responses to HIV-1, particularly during early
disease stages, are thought to be predominantly strain
speciﬁc. To investigate whether the antibodies that mediate
complement lysis activity are speciﬁc for the autologous virus
isolate or if cross-reactivity with heterologous isolates exists,
we evaluated the capacity of our panel of patient plasmas to
mediate lysis of the heterologous primary virus strain JR-FL.
All plasma samples derived from chronically infected
individuals, and 19 of 25 samples derived from acutely
infected individuals mediated lysis of the virus strain JR-FL
(Figure 3B). In agreement with the pattern seen for
autologous virolysis, the median of lysis activity against JR-
FL was almost three times as high in plasmas derived from
chronically than from acutely infected patients (p , 0.0001,
Mann-Whitney U test) (Table 2). In comparison, plasma from
uninfected healthy controls (n ¼ 11), induced no or only
marginal lysis that was lower than lysis activity seen in the
acute group (p ¼ 0.003, Mann-Whitney U test) (Table 2),
indicating that virolysis in infected patients is predominantly
mediated by HIV-1-speciﬁc antibodies.
In a further analysis, autologous and heterologous lysis
activities were assessed within each group and then separately
in the combined cohort. In general, plasma lysis activity
against heterologous and autologous viruses did not differ in
the acutely or the chronically infected group. The analysis of
the entire patient cohort also revealed no differences in lysis
Figure 2. Virolysis by Antibody and Complement
(A) Plasma from HIV-positive individuals specifically lyses HIV in presence
of active complement. Virus isolate JR-FL was incubated with comple-
ment (þ), without complement ( ), or with inactivated complement (Ci)
either in the absence of plasma ( ) or with plasma from uninfected
individuals (NHP) or from patient 106. One of three independent
experiments is shown.
(B) Up to four freeze-thaw cycles do not destroy intact HIV-1 virions. Virus
JR-FL was incubated in the presence of active complement with medium
(no plasma), with plasma from uninfected persons (NHP), or with plasma
from patient 106. Reaction mixtures were subjected to the indicated
number of freeze-thaw cycles and the effect on virus disintegration was
measured. One of two independent experiments is shown.
(C) IgG depletion reduces lysis activity. Plasma of uninfected individuals
(NHP) and of patients 117 and 113 were depleted of IgG with Protein G
Sepharose beads (darkened bars) and lysis activity was compared to
untreated plasma (open bars). Error bars indicate standard deviation of
triplicate measurements. Groups were compared using Mann-Whitney U
test.
doi:10.1371/journal.pmed.0030441.g002
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Complement Lysis of HIV In Vivoactivity (Table 2). Although the overall pattern of reactivities
against heterologous and autologous viruses was similar, with
plasma from chronically infected patients inducing higher
activities than did plasma from acutely infected individuals,
we found no evidence for a correlation between the lysis
activity against the autologous and heterologous virus strains
(rho¼0.03, p¼0.87 for acute; rho¼0.19, p¼0.30 for chronic
group) (Table 3), indicating that the type and speciﬁcities of
antibodies mediating these activities may not completely
overlap.
Analysis of the Anti-Env and Anti-Gag Responses
In the course of HIV-1 infection, commonly a strong, high-
titered antibody response to the structural viral proteins (Env
and Gag) is elicited [44–46]. Complement lysis of HIV virions
depends on antibodies that interact with the viral surface,
and thus most likely involve antibodies that recognize the
viral envelope proteins gp120 and gp41. It has been shown
that the majority of Env-speciﬁc antibodies recognize
epitopes that are inaccessible in the native oligomeric,
fusion-competent form of the virus envelope [47–52]. Anti-
bodies that bear neutralizing activity bind only to selected
epitopes on the viral envelope oligomer that are involved in
the interaction with the viral receptors or fusion. In contrast,
antibodies that activate complement could be theoretically
directed to any epitope accessible on the virion surface. To
obtain an initial insight into which classes of anti-HIV
antibodies mediate the complement lysis activity in patient
plasma, we determined antibody responses to the viral core
protein p24 and the Env proteins gp120 and gp41 with
recombinant proteins derived from the viral strains JR-FL
(gp120) and IIIB (p24 and gp41) (Table 1) [32]. As expected, all
antibody responses were lower in acute than in chronic
infection (Table 2) [32]. Since we had no recombinant gp41
from strain JR-FL available, we used the gp41 protein of the
closely related IIIB strain (89.2% sequence homology at the
amino acid level) to measure anti-gp41 responses in patient
plasma. We found that anti-gp120 and anti-gp41 titers were
associated in both the acute (rho ¼ 0.53, p ¼ 0.007) and the
chronic patient groups (rho ¼ 0.71, p , 0.0001) as well as
when all patients were analyzed together (rho ¼ 0.90, p ,
0.0001), indicating that anti-gp41 and anti-gp120 responses
may develop in parallel (Table 3 and Figure 4A). Anti-Env
responses did not appear to be correlated with anti-p24
responses during the chronic phase (unpublished data),
suggesting, as previously found [39], that anti-Env and anti-
Gag responses are differentially regulated. During the acute
phase, anti-gp120 and anti-p24 correlated signiﬁcantly (rho¼
0.76, p , 0.0001), probably reﬂecting the parallel maturation
of the immune response against all epitopes during this stage.
Impact of Anti-Env Responses on Complement Virolysis
In order to probe the impact of anti-Env antibody
responses on viral lysis activity, we ﬁrst analyzed the
interdependency between lysis activity against JR-FL and
antibody titers to the gp120 protein of this strain. We found a
strong correlation between anti-gp120 titers and lysis activity
when we analyzed the entire patient cohort (rho ¼ 0.87, p ,
0.0001) (Figure 4B and Table 3). This association between
anti-gp120 titers and lysis activity was more pronounced in
chronically infected individuals (rho ¼ 0.69, p , 0.0001) than
in acutely infected patients (rho¼0.41, p¼0.04). Likewise, we
observed a strong association between JR-FL lysis activity and
anti-gp41 antibody titers when all patients were analyzed
together (rho ¼ 0.83, p , 0.0001) (Figure 4C). When groups
were analyzed individually, the association in the chronically
infected patients alone was weaker (rho ¼ 0.58, p ¼ 0.0006)
and no interdependency was evident in the acute infection
group (rho ¼ 0.38, p ¼ 0.06). In contrast to the anti-Env
responses, antibody titers to the core protein p24 exhibited
no pronounced inﬂuence on the heterologous lysis activity
induced during acute and chronic infection (rho ¼ 0.37, p ¼
0.005 for the entire cohort) (Figure 4D). Taken together, our
analysis strongly suggests that anti-Env responses are central
in mediating complement lysis activity during both acute and
chronic disease stages.
Antibody titers against the autologous virus strains could
not be determined. Due to the heterogeneity of virus isolates
in our panel and the resulting variable sequence divergence
in the recombinant proteins used to determine antibody
titers, it was unlikely that we would see the same degree of
association between autologous lysis activity and binding
Figure 3. Lysis Activity against Virus in Plasma of Acutely and Chronically
Infected Patients
Complement-mediated lysis activity against autologous (A) and heter-
ologous (JR-FL) (B) virus was compared between acutely (blue triangles)
and chronically (green circles) infected individuals. HIV-specific lysis
activity is present at acute and chronic diseases stages but generally
higher during chronic infection. Crosses denote uninfected plasma
controls. Groups were compared using Mann-Whitney U test.
doi:10.1371/journal.pmed.0030441.g003
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Complement Lysis of HIV In Vivoactivity to the recombinant proteins. Nevertheless, a trend of
a positive nonsigniﬁcant association between gp120 binding
titers and lysis activity was observed in acutely infected
individuals (rho¼0.47, p¼0.02). However, no evidence for an
association was seen in chronically infected individuals (rho¼
 0.09, p ¼ 0.63). Equally, no association between lysis activity
to the autologous strain and reactivity to gp41 was seen in
either patient group (rho¼0.19, p¼0.37 and rho¼ 0.14, p¼
0.46 for the acute and chronic group, respectively). In
accordance with the interdependency of anti-Gag and anti-
Env responses during the acute phase, we observed a weak,
nonsigniﬁcant correlation between p24 responses and the
autologous lysis activity in acute patients (rho¼0.41, p¼0.04).
Longitudinal Assessment of Autologous Complement
Lysis Activity in Patient Plasma
Our cross-sectional analysis suggested that complement
lysis activity is mediated by anti-Env responses and may
increase when the antibody response broadens. To investigate
the development of the lysis activity more closely, we
monitored antibody responses and autologous complement
lysis activity over extended time periods in plasma of six
acutely HIV infected patients (Figure 5). Of these six
individuals one stayed treatment-naı ¨ve (patient 022). The
remaining ﬁve patients initiated antiretroviral treatment
during the acute infection phase and subsequently stopped
treatment after 12–31 months on successful antiretroviral
treatment. Lysis activity was measured against the autologous
strain derived at the ﬁrst specimen collection. Antibody
reactivity and lysis activity were subsequently measured solely
during the treatment-free periods.
As expected, titers of antibody to gp120 and gp41 increased
steadily in all patients, which was paralleled by an increase in
lysis activity. In the ﬁve patients who underwent treatment
interruption it is evident that along with viral load levels,
antibody responses and lysis activity rose. A direct impact on
in vivo viral load levels cannot be easily investigated in this
setting, since upon rebound it takes several weeks to months
before set points of viral load and immune responses are
reached. Collectively, our observation strongly suggests that
early antibody responses against the viral Env proteins gp41
Table 3. Correlation Analyses
Parameter 1 Parameter 2 n Rho
a p-Value
Autologous lysis versus Heterologous lysis acute group 25 0.03 0.87
Heterologous lysis chronic group 31 0.19 0.30
Anti-gp120 titer versus
b Anti-gp41 titer acute group 25 0.53 0.007
Anti-gp41 titer chronic group 31 0.71 ,0.0001
Anti-gp41 titer entire cohort 56 0.90 ,0.0001
Anti-gp120 titer versus Anti-p24 titer acute group 31 0.76 ,0.0001
Heterologous lysis versus
c Anti-gp120 titer acute group 25 0.41 0.04
Anti-gp120 titer chronic group 31 0.69 ,0.0001
Anti-gp120 titer entire cohort 56 0.87 ,0.0001
Heterologous lysis versus
d Anti-gp41 titer acute group 25 0.38 0.06
Anti-gp41 titer chronic group 31 0.58 0.0006
Anti-gp41 titer entire cohort 56 0.83 ,0.0001
Heterologous lysis versus
e Anti-p24 titer acute group 25 0.36 0.08
Anti-p24 titer chronic group 31 0.13 0.49
Anti-p24 titer entire cohort 56 0.37 0.005
Autologous lysis versus Anti-gp120 titer acute group 25 0.47 0.02
Anti-gp120 titer chronic group 31  0.09 0.63
Anti-gp41 titer acute group 25 0.19 0.37
Anti-gp41 titer chronic group 31  0.14 0.46
Anti-p24 titer acute group 25 0.41 0.04
Anti-p24 titer chronic group 31 0.29 0.11
Plasma neutralization versus Autologous virolysis acute group 25  0.34 0.10
Autologous virolysis chronic group 31 0.40 0.03
Heterologous virolysis acute group 25 NA NA
Heterologous virolysis chronic group 31 0.49 0.005
In vivo HIV-1 RNA versus
f Virolysis acute group 25  0.72 ,0.0001
Virolysis chronic group 31 0.18 0.33
In vivo HIV-1 RNA versus Anti-gp120 titer acute group 25  0.34 0.09
Anti-gp120 titer chronic group 31  0.04 0.85
Anti-gp41 titer acute group 25 0.01 0.98
Anti-gp41 titer chronic group 31 0.09 0.64
Anti-p24 titer acute group 25  0.22 0.29
Anti-p24 titer chronic group 31  0.20 0.27
aSpearman’s rank correlation.
bResults shown in Figure 4A.
cResults shown in Figure 4B.
dResults shown in Figure 4C.
eResults shown in Figure 4D.
fResults shown in Figure 8.
NA, not available
DOI: 10.1371/journal.pmed.0030441.t003
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Complement Lysis of HIV In VivoFigure 5. Longitudinal Assessment of Autologous Complement Lysis Activity in Patient Plasma
Lysis activity against autologous virus (red circles) of plasma from six acutely HIV-1-infected patients was measured longitudinally and plotted against
anti-gp120 titers (orange triangles), anti-gp41 titers (blue squares), and viral load (asterisks). At the first data point, patients were treatment-naı ¨ve and
acutely HIV infected. All patients (except patient 022) subsequently went on antiretroviral therapy for the indicated time periods. Time point 0 was
assigned to the date of treatment interruption and the remaining time points were calculated according to this time point. (A) Patient 022 (treatment-
naı ¨ve), (B) patient 015, (C) patient 003, (D) patient 016, (E) patient 026, and (F) patient 002.
doi:10.1371/journal.pmed.0030441.g005
Figure 4. Correlation Analysis of Antibody Responses and Virolysis Activity
(A) Correlation analysis of anti-gp120 and anti-gp41 antibody titers in plasma samples from the acute and chronic patient groups shows that titers to
the envelope glycoprotein correlate tightly independently of disease stage.
(B–D) Correlation analyses of heterologous lysis (JR-FL) with anti-gp120 (B) or anti-gp41 (C) revealed positive correlations, whereas anti-p24 (D) antibody
titers did not associate with heterologous lysis. This suggests that lysis activity is driven by envelope-specific antibodies.
Blue triangles denote acutely, green circles denote chronically infected patients. Spearman’s rank correlation coefficient (rho) and p-values are depicted
for the entire cohort (all), the acute patients (a), and the chronic patients (c). If antibody titers were below 1, the value 1 was used for statistical analysis.
doi:10.1371/journal.pmed.0030441.g004
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Complement Lysis of HIV In Vivoand gp120 mediate lysis activity against the autologous virus
strain.
Plasma Neutralization Activity
Neutralizing antibodies directed against the autologous
HIV strain can appear during the acute infection phase [4,5],
but are in general more pronounced during chronic disease
stages [1,6]. A central question in our analysis, therefore, was
to investigate whether neutralizing antibodies are elicited
alongside complement activating antibodies or if the latter
precede the neutralizing response. To this end we evaluated
the neutralizing activity mediated against autologous and
heterologous virus in our patient cohort.
Only six (24%) of the plasmas from the 25 acutely infected
patients and 14 (45%) from the group of 31 chronic patients
showed measurable autologous neutralization activity (NT90
. 40) (Figure 6A and 6B). A slightly higher autologous lysis
activity was observed among chronically infected patients
whose plasma had neutralizing activity against the autologous
viruses, although this difference did not reach signiﬁcance (p
¼ 0.02, Mann-Whitney U test). No difference was seen in the
acute group (p ¼ 0.13) (Table 2). Likewise, we observed no
correlation between autologous lysis and neutralization
activity in either group (Table 3). The latter could imply that
non-neutralizing antibodies contribute predominantly to the
lysis activity. However, we cannot exclude the possibility that
neutralizing antibodies are present at concentrations below
the detection level of the neutralization assay and that low
concentrations of these antibodies could sufﬁce to induce
virolysis. Nevertheless, neutralizing activity per se is low at
best in these patients and thus is unlikely to drive viremia
control.
Although none of the patient plasmas from the acute group
showed neutralizing activity against the heterologous virus
strain JR-FL (Figure 6C), 15 (48%) of the chronically infected
patients neutralized this virus (NT50 . 20) (Figure 6D).
Heterologous lysis activity was again higher among chroni-
cally infected patients with neutralizing activity (p ¼ 0.02,
Mann-Whitney U test) (Table 2). A marginal correlation
between heterologous lysis and neutralization activity was
observed in the chronic group (rho¼0.49, p¼0.005) (Table 3),
indicating that antibody reactivities involved in neutraliza-
tion and lysis of heterologous HIV-1 virions may overlap to
some extent.
Complement Lysis Leads to Reduction in Viral Infectivity
Since our virus lysis assay measures complement destruc-
tion under nonphysiological conditions (freeze-thaw cycle
and RNA digestion) we investigated whether virion lysis
occurs also under natural conditions and leads to a reduction
of viral infectivity. To circumvent nonspeciﬁc inhibitory or
enhancing effects of human plasma in our in vitro assay, we
chose assay conditions in which controls contained the
corresponding concentration of normal human plasma and
complement. To be able to compare effects of antibodies in
the absence of active complement (neutralization) and
inhibition induced in the presence of active complement
(neutralization and complement lysis), we chose plasma
dilutions that allowed simultaneous evaluation of both
effects. Thus, patient plasmas from the acute group, all of
which had marginal neutralization activity against the isolate
Figure 6. Neutralizing Antibodies Are Not the Major Constituent of Complement Lysis-Inducing Antibodies
Complement lysis activity of non-neutralizing and neutralizing patient plasmas was compared in the acute and the chronic infection cohorts.
Autologous neutralization (A and B) and heterologous (JR-FL) (C and D) neutralization are shown, with blue triangles denoting acutely, green circles
chronically infected patients. Each data point represents the mean of two or three independent experiments with plasma from the same patient.
Groups were compared using Mann-Whitney U test.
doi:10.1371/journal.pmed.0030441.g006
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Complement Lysis of HIV In VivoJR-FL, were studied at a dilution of 1:40; chronic patients,
whose plasma generally had higher neutralization activity,
were studied at a dilution of 1:200. Each patient group was
assessed separately, which allowed us to use two different
plasma dilutions. The latter was necessary, because otherwise
neutralization activity would have dominated the readout in
the chronic group. In the majority of patients the presence of
active complement increased the inhibitory effect of the
patient plasma (Figure 7). Median inhibition was markedly
lower when complement was inactivated, both in the acute (p
, 0.0001, Wilcoxon signed-rank test) (Table 2) and the
chronic group (p ¼ 0.0009), demonstrating that complement
lysis reduces viral infectivity.
Impact of Complement Lysis on Viremia Control In Vivo
Both HIV-1-speciﬁc T cell activity and—somewhat de-
layed—humoral immune responses develop early in HIV
infection. The initial rise in cytotoxic T lymphocytes
responses is often associated with a decline in viremia shortly
after infection [53]. Although neutralizing activity of anti-
bodies in patient sera during the acute phase can be found
[4,5], it is not clear to what extent these antibodies contribute
to viral containment. Even less is known about the effects of
complement lysis mediating antibodies in vivo. Since our
analyses thus far had clearly shown that complement-
activating antibodies are elicited soon after infection, we
next investigated whether these antibodies have a clear
impact on viremia control in vivo. To this end we probed
whether interdependencies existed between autologous or
heterologous lysis activities and the plasma viral load
measured at the time of plasma and virus collection.
We found that lysis activity against autologous plasma
inversely correlated with the in vivo viral load (RNA copies/ml
of plasma) in the acute group (rho ¼  0.72, p , 0.0001), but
not in the chronic group (rho ¼ 0.18, p ¼ 0.33) (Figure 8 and
Table 3). Our assessment of the in vivo activity of the viral
lysis activity solely focuses on the potential contribution of
the HIV-speciﬁc antibodies in the patient plasma. In vivo lysis
activity may further vary due to variations in complement
activity inﬂuenced by different genetic backgrounds and
disease progression. No interdependency between CD4 levels
and virolysis activity or virus load existed in the acute cohort
(unpublished data). In contrast to autologous lysis activity,
heterologous lysis activity and viral load did not correlate,
indicating that isolate-speciﬁc antibodies may dominate
virolysis activity in vivo. Antibody titers to the viral proteins
gp120, gp41, and p24 showed no correlation with the viral
load in both the acute and the chronic cohorts (all rho values
  0.34, p   0.09) (Table 3). Hence, the inverse association
between autologous lysis activity and viral loads during the
acute phase does not simply reﬂect the appearance of binding
antibodies during this period in these patients. Taken
together our data demonstrate that increased antibody-
mediated complement lysis coincides with lower viral loads
in the acute phase. Therefore, complement lysis could
potentially function as an early immune defense mechanism
against HIV-1 that impacts on viremia control in the acute
infection phase, during which the adaptive immune response
has not yet fully matured.
Discussion
In recent years substantial effort has been put into
investigating the humoral immune response to HIV-1. While
neutralizing antibodies are considered a correlate of protec-
tion against HIV-1 and a necessary component of vaccine-
induced immune responses, the role of effector mechanisms
mediated by anti-HIV antibodies in immune control remains
largely unclear. In the present study we investigated the
efﬁcacy of the humoral immune response elicited during
acute and chronic disease stages in inducing complement-
dependent lysis of HIV virions. Evidence obtained through a
novel complement virion lysis assay suggests that antibody-
mediated complement lysis in the plasma of HIV-1-infected
individuals has been underestimated in the past. Previously
used virolysis assays mostly relied on the measurement of
reverse transcriptase [54] and p24 antigen released from lysed
virions [24,25,55], which limited their use in measuring
complement lysis activity directly in patient plasma because
antibodies speciﬁc for reverse transcriptase and p24 can
interfere with the detection of these proteins following
virolysis. The development of a novel, highly sensitive and
quantiﬁable assay for virolysis-mediating antibody responses
in plasma samples was thus key for the current study, and it
allowed us to investigate complement lysis in patient samples
directly by quantifying viral RNA.
We found that, in most patients, antibodies are elicited
very early after infection (, 3 mo) that induce complement-
Figure 7. Influence of Complement on Viral Infectivity In Vitro
Inhibitory activity of patient plasma against the heterologous virus JR-FL
was measured in presence of active (Cþ) or heat-inactivated (Ci)
complement on TZM-bl cells. Blue triangles denote acutely, green circles
chronically infected patients. Data points are means of two independent
experiments with plasma from the same patient. Differences in inhibition
between inactivated and active complement within the subgroups were
compared using Wilcoxon signed-rank test. The results demonstrate that
complement increases the inhibitory activity of HIV specific antibodies in
vitro.
doi:10.1371/journal.pmed.0030441.g007
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Complement Lysis of HIV In Vivomediated lysis of the autologous virus and thus could
contribute to viremia control during the acute phase of
HIV-1 infection. The latter is signiﬁed in our study by a tight
inverse correlation between lysis activity and in vivo-
measured viral loads. Our results corroborate the ﬁndings
by Aasa-Chapman and coworkers, who recently reported
complement lysis activity in sera of some acutely infected
individuals [23]. In our study, lysis activity was in general
higher during chronic infection, probably reﬂecting the
elevated antiviral antibody responses in later stages of the
infection. Unlike in acute infection, however, no association
between complement lysis activity and the viral set point was
seen in chronically infected patients. Virolysis, if active in
vivo, should destroy virions in both disease stages and even
more so during chronic infection, as the in vitro-measured
activity is higher then. A possible explanation of these
contrasting observations in acute and chronic infection is
that complement lysis-activating antibodies may be impor-
tant only early in infection, when other adaptive immune
responses have not yet fully matured. In chronic infection the
overall inﬂuence of these complement-activating antibodies
may be still present, but their impact lower or negligible
because neutralizing antibody and cellular immune responses
have matured. Thus the effect of virolysis on viral load levels
may only be measurable during the acute phase, because
during later stages of the infection other immune functions
have developed that are more powerful and therefore
determine the viral set point. Virolysis activity, while still
present, would then have a comparatively small effect on in
vivo virus loads.
In support of the differences between acute and chronic
group we found that, particularly during the acute phase,
complement lysis appeared to be predominantly mediated by
non-neutralizing antibodies. Lysis activity against the heter-
ologous strain JR-FL was observed despite the absence of
neutralizing antibodies against this virus in acutely infected
patients. Likewise, lysis and neutralization activity against the
autologous viruses showed no interdependency. Although in
the chronic cohort higher lysis activity was found in patients
that harbored neutralizing activity, we observed no direct
relationship of these reactivities against the autologous virus,
and only a minor inﬂuence in the heterologous system.
Nevertheless, we cannot exclude the possibility that neutral-
izing antibodies at concentrations lower than the detection
limit of the neutralization assay are present and contribute to
virolysis activity.
The role of complement in HIV pathogenesis has been a
matter of debate for many years. While several reports have
proposed that complement-dependent virus lysis occurs in
vivo [43,56], and that complement can boost the effect of
neutralizing antibodies both in vivo and in vitro [21–23],
other groups have demonstrated a pronounced resistance of
HIV to complement lysis in vitro [24–26,55,57,58]. Moreover,
opsonization of virus with antibodies and complement has
been shown to enhance viral infectivity and transmission in
vitro [12,13,28–31]. Which of these complement activities
occur in vivo and what their relative contributions are in
inhibiting or enhancing viral replication, remain currently
unknown. Whether complement lysis activity is outweighed
by more speciﬁc adapted immune responses in chronic
infection, as suggested above, or whether at later disease
stages enhancing effects of antibodies and complement
emerge and reduce the impact of lysis activity are questions
bearing further investigation.
The factors that direct complement action to either lysis or
enhancement have not been fully deﬁned. While our study
demonstrates inhibitory effects of complement and antibody
in early HIV infection, complement-dependent enhancement
of HIV infection of complement receptor-bearing cells likely
occurs as well in vivo. Complement concentration may vary at
different disease stages [43,59–62]; thus, in vivo, individual
lysis activity could differ due to ﬂuctuations in complement
supply.
Moreover, complement concentrations in tissue are only in
the range of 10%–20% of the levels in serum [63–65]. Thus
the relative contribution of virus lysis and enhancement in
tissue and in the periphery may differ and needs to be
investigated. Further studies will be needed to unravel
whether the beneﬁcial or the detrimental effects of comple-
ment and antibody dominate in vivo.
It is currently also not known whether antibodies that
mediate complement lysis and enhancement are directed to
the same epitopes. Nevertheless, it seems feasible that their
reactivities overlap to some extent. Our data indicate that if
enhancing activity impacts on virus replication in vivo, it
appears not to be a direct consequence of high antibody
titers, as we observed no notable interdependency between
binding antibody titers to HIV and viral loads. We demon-
Figure 8. Correlation Analysis of Complement Virolysis and In Vivo Viremia Levels
In vitro-determined autologous virolysis activity was correlated with in vivo HIV-1 RNA copies measured per milliliter of plasma in the acutely infected
group (A) and the chronically infected group (B). Correlations were evaluated using Spearman’s rank correlation. Our data demonstrate that increased
antibody-mediated complement lysis coincides with lower viral loads in the acute phase. No evidence was found for a similar correlation in the
chronically infected group.
doi:10.1371/journal.pmed.0030441.g008
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Complement Lysis of HIV In Vivostrated, however, that also under culture conditions, comple-
ment in concert with HIV-1-speciﬁc antibodies reduces viral
infectivity, which further supports a role for virus lysis in
vivo.
We determined in our study that complement lysis activity
is mediated by anti-Env antibodies, as demonstrated by the
tight correlation between lysis activity and antibody titers to
gp120 and gp41. While neutralizing antibodies are known to
recognize native viral Env oligomer epitopes that are involved
in receptor binding and fusion, complement-activating anti-
bodies are not limited to these sites. Additionally, non-
neutralizing antibodies binding to the oligomer, or anti-
bodies reacting with gp120 monomers or with epitopes on
gp41 that are exposed after shedding of gp120, could
potentially activate complement if bound to the virion in
sufﬁcient densities.
A more detailed characterization of the antibodies medi-
ating lysis activity will be particularly important if comple-
ment-activating antibodies are to be considered a component
of effective vaccines.
Our ﬁnding that HIV-1 is susceptible to lysis mediated by
speciﬁc antibodies in patient sera and complement is in
agreement with a previous study by Sullivan and coworkers,
who showed that virus derived from patient plasma can be
lysed in the presence of complement due to virion-bound
antibodies that activate the complement system [43]. While
this study provided initial evidence that complement lysis of
HIV-1 may occur in vivo, it was limited to the analysis of
patient samples with high viral load due to the inherent
insensitivity of the assay used. The range of lysis activity
found in this ex vivo analysis (14%–86% lysis) corresponds
closely with the values obtained in our study. The profound
complement lysis seen in our study and, most importantly,
the inverse correlation between lysis activity and in vivo viral
loads during the acute phase strongly suggest that antibody-
mediated complement lysis could contribute to viremia
control and may therefore be a defense mechanism in vivo.
Several recent reports have emphasized that complement
activation boosts humoral and cellular immune responses [8].
Consequently, complement-stimulating antibodies, besides
mediating direct lysis of virions, might have an important
function in aiding the development of immune responses to
HIV both in natural infection and in responses to vaccines.
While our study demonstrates that presence and magni-
tude of autologous antibody-mediated complement lysis of
HIV-1 coincide with increased viremia control during the
acute infection phase, direct associations cannot be formally
proven. Immune functions and the timing of their appear-
ance during the course of early HIV-1 are intertwined, and it
is therefore difﬁcult to ascertain direct relationships.
Activities of cytotoxic T cells, neutralizing antibodies, anti-
bodies that mediate antibody-dependent cellular toxicity,
opsonization, aggregation, phagocytosis and—as our current
report suggests—antibodies that mediate virus lysis via
activation of the complement system will impact on viral
spread in vivo. Total or neutralizing antibody titers or CTL
activity, however, have not been proven to reliably predict
viremia levels in the past [39,66–69]. While cellular immune
responses were not assessed in our study, the fact that
virolysis activity induced by complement and antibody
inversely correlated with in vivo viral loads, but not with
binding antibody titers per se nor with neutralizing activities,
leaves room for a scenario in which virolysis has an impact on
viral load levels in vivo. Nevertheless, subsequent studies will
be required to unravel the exact associations between these
diverse immune functions and to assess their individual
impact. Based on our current study, we hypothesize that
complement lysis activity induced by speciﬁc antibodies may
be an additional player in the network of immune function
countering HIV replication in vivo and that, therefore, the
impact of these antibodies in vivo should be further
evaluated, as they could be a critical component of vaccine-
induced immunity to HIV-1.
Supporting Information
Figure S1. The Extent of Lysis Is Independent of the Amount of Virus
Input
The varying amounts of RNA input into the autologous assays were
correlated with measured autologous virolysis activities. Correlation
was evaluated using Spearman’s rank correlation (n¼56, rho¼ 0.09,
p ¼ 0.53, two-tailed).
Found at doi:10.1371/journal.pmed.0030441.sg001 (841 KB DOC).
Table S1. Control Group Demographics
Found at doi:10.1371/journal.pmed.0030441.st001 (35 KB DOC).
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Editors’ Summary
Background. If untreated, most people who become infected with the
human immunodeficiency virus (HIV) eventually develop acquired
immunodeficiency syndrome (AIDS). Over time, HIV infects and kills
their CD4 T lymphocytes—immune system cells that stimulate B
lymphocytes to make antibodies (proteins that recognize and destroy
infectious agents) and that help CD8 T lymphocytes to kill cells that
contain viruses and bacteria. The loss of CD4 T lymphocytes—a central
player in ‘‘adaptive immunity’’—leaves patients very susceptible to
infections. However, the immune system does not die quietly. It does its
best to fight HIV infection by mounting a cell-mediated immune
response in which T lymphocytes attack HIV-infected cells. It also mounts
a ‘‘humoral’’ immune response in which antibodies that recognize HIV
are made. Some of these are neutralizing antibodies, which prevent HIV
entering its host cells and replicating. Other antibodies may limit viral
spread by inducing destruction of the virus. One way they can do this is
by activating another part of the immune system called the complement
system, which can break open and kill viruses (this is known as antibody-
mediated complement lysis). In addition, antibodies and complement
can coat the HIV virus particles so that phagocytes (for instance
macrophages—yet another type of immune system cell) engulf and
destroy the virus.
Why Was This Study Done? The role that humoral immunity plays in
fighting HIV infection is complex and poorly understood. In particular, it
is not clear whether the complement system helps to stop the spread of
HIV or whether it inadvertently helps it to spread by facilitating its entry
into host cells. It is important to understand as much as possible about
the humoral immune response to HIV infection so that vaccines can be
designed to provide maximum protection against HIV. In this study, the
researchers have investigated whether antibody-mediated complement
lysis controls the amount of virus in the blood of patients infected with
HIV.
What Did the Researchers Do and Find? The researchers collected
plasma (the liquid part of blood that contains circulating antibodies)
from patients recently infected with HIV (acute infection) and patients
who had been infected for some time (chronically infected). They also
isolated HIV from each of the patients—so-called autologous virus. They
then used a sensitive molecular biology assay to test each plasma sample
for its ability to lyse the autologous virus (and also a standard virus)
when supplied with complement from a healthy donor. Most of the
plasma samples were able to lyse HIV, although the samples taken from
chronically infected patients generally caused more lysis than those from
acutely infected patients. In the chronically infected patients, the level of
lysis induced was not related to the amount of virus in the patients’
blood (viremia). However, plasma taken from acutely infected patients
with higher viral loads was less active in the lysis assay than plasma taken
from patients with lower viral loads. Finally, the researchers showed that
the levels of antibodies in the various plasma samples to the two
envelope proteins of HIV correlated strongly with the ability of each
sample to lyse the standard virus and that these antibodies were mainly
non-neutralizing antibodies.
What Do These Findings Mean? By showing that antibody-mediated
complement lysis of HIV in the laboratory is inversely related to the
patients’ viral loads during acute infection, these findings suggest (but
do not prove) that antibody-mediated complement lysis of HIV
contributes to the control of viremia early in HIV infections. But, the
importance of this form of humoral immunity in combating HIV
infections remains uncertain, since complement has the potential to
enhance as well as block viral spread. Further work is needed to unravel
which of these effects is dominant in patients and to characterize fully
the antibodies that activate complement. Nevertheless, the results of this
study suggest that complement-activating antibodies should be
considered in future attempts to design an effective HIV vaccine.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030441.
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